Pharmaceutical Commerce (independent trade) - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Pharmaceutical Commerce (independent trade)

Pharmaceutical Commerce (independent trade)

Publication
0 followers

Business-side publication on pharma supply chain, distribution, and market access.

Recent Posts

Cybersecurity and AI in the Era of Home-Based Care Logistics
News•Feb 27, 2026

Cybersecurity and AI in the Era of Home-Based Care Logistics

Kenco’s vice‑president of life sciences, Tim McClatchy, detailed how the firm is hardening cybersecurity across its manufacturer‑to‑home delivery network while deploying AI to streamline labor planning and route optimization. He explained the specific encryption and verification steps used at each handoff, and how recent FDA and HHS regulatory updates forced tighter data‑tracking protocols. McClatchy also projected that third‑party logistics providers will increasingly dominate home‑based care supply chains over the next decade, reshaping the industry’s operational model.

By Pharmaceutical Commerce (independent trade)
FAQ: Inflation Reduction Act and Medicare Drug Pricing
News•Feb 27, 2026

FAQ: Inflation Reduction Act and Medicare Drug Pricing

The Inflation Reduction Act reshapes Medicare Part D by granting CMS authority to negotiate prices for high‑cost drugs and instituting a $2,100 annual out‑of‑pocket cap for beneficiaries starting this year. The first ten drugs, including Ozempic and Wegovy, will have negotiated...

By Pharmaceutical Commerce (independent trade)
Pharma Pulse: The Oral GLP-1 Battle and GSK’s Billion-Dollar Breath of Fresh Air
News•Feb 27, 2026

Pharma Pulse: The Oral GLP-1 Battle and GSK’s Billion-Dollar Breath of Fresh Air

Eli Lilly’s oral GLP‑1 small‑molecule orforglipron demonstrated greater A1C reduction and weight loss than oral semaglutide, while offering flexible dosing without fasting. GSK announced a $950 million acquisition of 35Pharma, securing HS235, an activin‑signaling inhibitor aimed at pulmonary hypertension. The deal taps...

By Pharmaceutical Commerce (independent trade)
Pharma Pulse: MRNA Legal Wars and the Community Pharmacy Shield
News•Feb 23, 2026

Pharma Pulse: MRNA Legal Wars and the Community Pharmacy Shield

BioNTech has filed a Delaware patent‑infringement lawsuit against Moderna, accusing the latter’s next‑generation COVID vaccine mNEXSPIKE of using BioNTech’s streamlined mRNA design. The disputed shot is projected to generate about 55 % of Moderna’s COVID revenue this season, making the case...

By Pharmaceutical Commerce (independent trade)
Supreme Court Rejection of Trump Tariffs Has Nuanced Implications for Pharma Importers
News•Feb 20, 2026

Supreme Court Rejection of Trump Tariffs Has Nuanced Implications for Pharma Importers

The Supreme Court struck down the broad tariffs imposed under the International Emergency Economic Powers Act, but left Section 232 duties untouched. Because most pharma tariffs were issued under Section 232, the ruling does not eliminate the targeted tariffs on drug imports....

By Pharmaceutical Commerce (independent trade)
Pharma Pulse: J&J’s $1B Cell Therapy Hub and Hims & Hers’ Global Expansion
News•Feb 20, 2026

Pharma Pulse: J&J’s $1B Cell Therapy Hub and Hims & Hers’ Global Expansion

Johnson & Johnson announced a $1 billion investment to build a next‑generation cell‑therapy manufacturing facility in Montgomery County, Pennsylvania, slated to support 500 skilled jobs. The hub is a key element of J&J’s $55 billion U.S. manufacturing, R&D, and technology strategy. Meanwhile,...

By Pharmaceutical Commerce (independent trade)
From Launch to Loss of Exclusivity- Reducing Access and Affordability Barriers Across the Brand Lifecycle
News•Feb 19, 2026

From Launch to Loss of Exclusivity- Reducing Access and Affordability Barriers Across the Brand Lifecycle

CoverMyMeds outlines how access and affordability challenges evolve across a biopharma brand’s lifecycle, from launch through loss of exclusivity, and offers actionable, data‑driven strategies to mitigate them. The firm emphasizes real‑time analytics, provider‑focused tools, and tailored patient assistance to reduce...

By Pharmaceutical Commerce (independent trade)
CMS Broadens Drug Price Negotiations to Part B Therapies
News•Feb 19, 2026

CMS Broadens Drug Price Negotiations to Part B Therapies

The Centers for Medicare & Medicaid Services announced a third round of drug price negotiations that for the first time includes Part B physician‑administered therapies. By extending the Inflation Reduction Act’s pricing provisions to infused medicines, the move pulls doctors into...

By Pharmaceutical Commerce (independent trade)
Pharma Pulse: FDA’s Moderna Reversal and Eli Lilly’s $100 Million IL-6 Bet
News•Feb 19, 2026

Pharma Pulse: FDA’s Moderna Reversal and Eli Lilly’s $100 Million IL-6 Bet

The FDA has reversed its earlier refusal-to-file and will review Moderna’s seasonal mRNA influenza vaccine, with a decision slated for August 5, 2026. Moderna now seeks full approval for adults aged 50‑64 and accelerated approval for those 65 and older. Meanwhile, Eli Lilly...

By Pharmaceutical Commerce (independent trade)
Patent Cliff Pressures to Drive Big Pharma M&A
News•Feb 18, 2026

Patent Cliff Pressures to Drive Big Pharma M&A

The looming patent cliff, projected to strip up to $300 billion in annual drug sales by 2032, is keeping large pharma firms focused on strategic acquisitions rather than triggering a sudden surge in deal volume. Dan Chancellor of Norstella notes that...

By Pharmaceutical Commerce (independent trade)